The Next Generation of GLP-1 Medications: What's Coming in 2026 and Beyond

Retatrutide is Eli Lilly's investigational triple agonist — a single molecule that activates three gut hormone receptors at once: GLP-1, GIP, and glucagon. The combination is mechanically distinct from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). The glucagon receptor activation increases energy expenditure — your body burns more calories at rest — while still preserving the appetite-suppressing effects of GLP-1 and GIP. In the Phase 2 TRIUMPH-1 trial (NEJM 2023), participants on the highest dose of retatrutide lost a mean of 24.2% of body weight at 48 weeks, with weight still trending downward at trial end. That's roughly double Wegovy's average and meaningfully above Zepbound. Phase 3 TRIUMPH trials are underway, with FDA submission expected in 2026 and possible launch in late 2026 or 2027.

Orforglipron is the most advanced oral once-daily GLP-1 in development — and unlike oral Rybelsus, it doesn't require fasting or strict water intake. It's a small-molecule GLP-1 receptor agonist (not a peptide), so it survives stomach acid and absorbs well. In the ATTAIN-1 Phase 3 trial reported in 2025, orforglipron produced 14.7% weight loss at 72 weeks in adults without diabetes — roughly comparable to injectable semaglutide. For people who hate injections, this is a meaningful development. Lilly has indicated FDA filing in late 2025 with potential launch in 2026. If approved, orforglipron could expand access dramatically — manufacturing pills is cheaper and faster than peptides, which may help with the persistent supply shortages we've seen with [compounded semaglutide vs brand options](/blog/compounded-semaglutide-vs-brand-cost-safety-2026).

Amycretin (Novo Nordisk) is unusual: it's a single peptide molecule that activates both GLP-1 and amylin receptors. Amylin is a hormone co-secreted with insulin that slows gastric emptying and increases satiety — and combining it with GLP-1 has produced exceptionally strong early results. The Phase 1 trial showed up to 22% weight loss at 36 weeks with the injectable form, and the oral version produced 13.1% loss at 12 weeks. Phase 2 trials are ongoing. Amycretin is years behind retatrutide and orforglipron in development, but its dual oral/injectable strategy could make it commercially flexible. Expected launch: 2028 or later.

Survodutide is a dual GLP-1/glucagon agonist from Boehringer Ingelheim and Zealand Pharma, currently in Phase 3. The Phase 2 weight-loss data showed about 19% weight loss at 46 weeks. But what makes survodutide distinct is its strong signal in MASH (metabolic dysfunction-associated steatohepatitis) — fatty liver disease — where it produced resolution of MASH in up to 83% of patients in a separate Phase 2 trial. MASH affects roughly 1 in 4 adults globally and is rising fast. Survodutide could become the first GLP-1-class drug with a specific MASH indication, alongside its obesity uses.

Probably yes — eventually. Two trends point that way. First, orforglipron is a small molecule, not a peptide, so it can be manufactured at a fraction of the cost of injectable peptides. Second, multiple manufacturers competing in the GLP-1 class (Lilly, Novo, Boehringer, Roche, Pfizer, Amgen) will likely drive list prices down over time, much like the statin class did in the 2000s. That said, in the first 1–2 years post-launch, expect new drugs to be priced at or above current GLP-1 levels — manufacturers recover R&D costs early. Insurance coverage will be the main practical lever for most patients, just as it is today. The [compounded semaglutide vs brand cost guide](/blog/compounded-semaglutide-vs-brand-cost-safety-2026) walks through current pricing trade-offs.

Several companies are working on monthly or even quarterly GLP-1 formulations to reduce injection burden. Amgen's maridebart cafraglutide (MariTide) is a long-acting GLP-1/GIP combination dosed monthly, with Phase 2 data showing ~15% weight loss at 24 weeks. Roche's CT-388 is another long-acting candidate in Phase 2. Once-monthly dosing could meaningfully improve adherence — missing one weekly injection means missing a quarter of your dose; missing one monthly injection is a much bigger gap, so longer-acting forms also raise design questions about safety windows. Expect these to enter the market 2027–2029.

Almost certainly no — at least, not without your provider's input. The drugs available today (Wegovy, Zepbound, Mounjaro, Ozempic) work very well for most people, and waiting 2–3 years for a marginal improvement carries real metabolic cost. If you're carrying excess weight that's affecting cardiovascular risk, joint pain, sleep, or quality of life, treating now matters. New drugs typically cost more in the early years and have less long-term safety data. For most people, the right strategy is: start with an approved option, track your response, and discuss switching if a new drug emerges that's clearly better for your specific situation. If you've plateaued on a current drug, our [weight loss plateau on Wegovy guide](/blog/weight-loss-plateau-on-wegovy-what-to-do-when-the-scale-stops) covers next-step options today.

The bigger picture is that obesity is finally being treated as a chronic metabolic disease rather than a personal failing. The pipeline includes drugs targeting genes (gene therapy for monogenic obesity), the gut microbiome, brain reward circuits, and inflammation — not just appetite. Over the next decade, we'll likely see personalized obesity medicine: drugs matched to your genotype, hormone profile, or specific obesity subtype. Today's GLP-1 era will look in 10 years much like the first statins look now — foundational, but eclipsed by more refined options. The good news is that even today's medications are reshaping cardiovascular and metabolic health at a population level. As always, all medical decisions belong to you and your healthcare provider — pipeline reports are for context, not prescriptions.